The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells

• Published in: Atherosclerosis Vol. 197; no. 2; pp. 829 - 839
• Main Authors: Mausner-Fainberg, Karin, Luboshits, Galia, Mor, Adi, Maysel-Auslender, Sophia, Rubinstein, Ardon, Keren, Gad, George, Jacob
• Format: Journal Article
• Language: English
• Published: Amsterdam Elsevier B.V 01.04.2008; Elsevier
• Subjects: Adult; Animals; Atherosclerosis; Atherosclerosis (general aspects, experimental research); Atorvastatin Calcium; Biological and medical sciences; Blood and lymphatic vessels; Blood vessels and receptors; Cardiology. Vascular system; Cardiovascular; Forkhead Transcription Factors - drug effects; Foxp3; Fundamental and applied biological sciences. Psychology; Heptanoic Acids - pharmacology; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology; Hypercholesterolemia - drug therapy; Immune response; Lovastatin - analogs & derivatives; Lovastatin - pharmacology; Medical sciences; Mice; Mice, Inbred C57BL; Pravastatin - pharmacokinetics; Pyrroles - pharmacology; Statins; T cells; T-Lymphocytes, Regulatory - drug effects; Up-Regulation; Vertebrates: cardiovascular system; Immune response; T cells; Foxp3; Statins; Atherosclerosis; HMG; Enzyme; Cardiovascular disease; Statin derivative; Gonadotropin; Vascular disease; T-Lymphocyte; Oxidoreductases; Antilipemic agent; Reductase

Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) are in widespread use due to their LDL reducing properties and concomitant improvement of clinical outcome in patients with and without preexisting atherosclerosis. Considerable evidence suggests that immune mediated mechan...